Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1a/b trial assessing single ascending dose (SAD)/multiple ascending dose (MAD) of BT409 in healthy volunteers and idiopathic Parkinson's disease patients

Next Previous
Trial Profile

Phase 1a/b trial assessing single ascending dose (SAD)/multiple ascending dose (MAD) of BT409 in healthy volunteers and idiopathic Parkinson's disease patients

Status: Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 03 Feb 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs BT 409 (Primary)
  • Indications Parkinson's disease
  • Focus Adverse reactions; First in man

Most Recent Events

  • 15 Jan 2026 According to Brenig Therapeutics media release, the company has initiated the single ascending dose (SAD)/multiple ascending dose (MAD) study, with first dosing anticipated in early Q1 2026.
  • 15 Jan 2026 Status changed from planning to not yet recruiting.
  • 21 Nov 2025 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top